Aclaris Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Aclaris Therapeutics, Inc. (ACRS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.50 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-06
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $2.45, a 37.64% increase year-over-year.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $1.78, a 106.98% increase year-over-year.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $0.86, a 92.79% decline year-over-year.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $11.92, a 19.56% increase year-over-year.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $1.61, a 20.15% increase from fiscal 2024.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $1.34, a 87.80% decline from fiscal 2023.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $10.98, a 10.35% increase from fiscal 2022.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $9.95, a 36.50% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.50 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $2.45 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $1.61 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $1.60 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $1.65 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $1.78 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $1.34 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $0.86 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $0.86 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $0.86 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $10.98 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $11.04 10-Q · filed 2023-11-06 | |||
| 2023-06-30 | $11.42 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $11.92 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $9.95 10-K · filed 2024-02-27 | |||
| 2022-09-30 | $9.83 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $9.89 10-Q · filed 2022-08-03 | |||
| 2022-03-31 | $9.97 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $15.67 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $15.86 10-Q · filed 2021-11-02 | |||
| 2021-06-30 | $15.96 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $16.15 10-Q · filed 2021-05-07 | |||
| 2020-12-31 | $0.93 10-K · filed 2023-02-23 | |||
| 2020-09-30 | $0.93 10-Q · filed 2020-11-04 | |||
| 2020-06-30 | $0.93 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | $0.93 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $4.63 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $4.63 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $6.22 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $6.22 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | $16.55 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $16.75 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | $17.04 10-Q · filed 2018-08-03 | |||
| 2018-03-31 | $17.43 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | $20.28 10-K · filed 2020-02-25 | |||
| 2017-09-30 | $20.41 10-Q · filed 2017-11-07 | |||
| 2017-06-30 | $20.81 10-Q · filed 2017-08-08 | |||
| 2017-03-31 | $21.06 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | $21.16 10-K · filed 2019-03-18 | |||
| 2016-09-30 | $15.83 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $15.79 10-Q · filed 2016-08-11 | |||
| 2016-03-31 | $16.75 10-Q · filed 2016-05-11 | |||
| 2015-12-31 | $13.84 10-K · filed 2018-03-12 | |||
| 2015-09-30 | $8.34 10-Q · filed 2015-12-03 | |||
| 2014-12-31 | $1.38 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |